CClinicalTrials.gg
CompletedNCT02910284Updated Oct 20, 2017

Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity

An observational study in Genital Herpes Simplex Type 2, sponsored by Genocea Biosciences, Inc.. Completed at 13 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2017-10-20.

Sponsored by Genocea Biosciences, Inc. · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
140
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This study is a follow-up study from Study GEN-003-002 to evaluate long-term efficacy and immunogenicity of GEN-003 in subjects with genital HSV-2 infection.

02

Conditions studied

  • Genital Herpes Simplex Type 2

Keywords

  • HSV
  • Herpes
  • Genital Herpes
03

In context

Herpes Simplex

305 studies on the registry are indexed under Herpes Simplex; 31 are open to participants now.

This study's enrollment of 140 is below the median of 180 across 55 observational studies indexed under Herpes Simplex.

Browse Herpes Simplex studies →

Lead sponsor

Genocea Biosciences, Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects who received at least 1 dose of active GEN-003 and completed the GEN-003-002 study.

Inclusion criteria

  1. Completion of Study GEN-003-002
  2. Receipt of at least 1 dose of GEN-003 (any dose combination) in Study GEN-003-002.
  3. Collection of at least 45 of 56 anogenital swabs during the Month 11 to 12 swab collection period in Study GEN-003-002.
  4. Willing and able to provide written informed consent.
  5. Willing to perform and comply with all study procedures, including attending clinic visits as scheduled.
  6. For each swab collection period, willing to not use HSV-2 antiviral therapy from 14 days before the swab collection period through the end of the period.

Exclusion criteria

Exclusion Criteria:

  1. Any important protocol deviation in Study GEN-003-002.
  2. Use of HSV-2 antiviral therapy within 14 days before the beginning of Swab Collection Period 1.
  3. Use of topical steroids or antiviral medication in the anogenital region within 14 days before the beginning of Swab Collection Period 1.
  4. Use of tenofovir, lysine, or other medication or supplement known or purported to affect HSV outbreak frequency or intensity within 14 days before the beginning of Swab Collection Period 1.
  5. Immunocompromised individuals, including those receiving immunosuppressive doses of corticosteroids (more than 20 mg of prednisone given daily or on alternative days for 2 weeks or more within 6 months before the Visit 1, any dose of corticosteroids within 30 days before Visit 1, or high-dose inhaled corticosteroids [>960 µg/day of beclomethasone diproprionate or equivalent]) or other immunosuppressive agents.
  6. Presence or history of autoimmune disease, regardless of current treatment.
  7. Receipt of a vaccine containing HSV-2 antigens other than GEN-003.
  8. Pregnant women.
  9. History of drug or alcohol abuse that, in the opinion of the Investigator, would interfere with the patient's ability to comply with the requirements of the study.
  10. Onset of an AESI since Month 12 in study GEN-003-002.
  11. Other active, uncontrolled comorbidities that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the study requirements.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
140 participants (actual)
Patient registry
No

Interventions

  • BiologicalObservational
06

What researchers measure

Primary outcomes

  1. Long-term effect of GEN-003 on anogenital Herpes simplex virus type 2 (HSV-2) shedding (percent of anogenital swabs positive for HSV-2 DNA by PCR)

    Time frame: Up to 48 months post-dose

  2. Long-term effect of GEN-003 on anogenital Herpes simplex virus type 2 (HSV-2) shedding (magnitude of HSV-2 viral shedding by PCR)

    Time frame: Up to 48 months post-dose

Secondary outcomes

  1. Long-term effect of GEN-003 on HSV-lesion rate (percent of days with genital lesions present) during the swab collection periods

    Time frame: Up to 48 months post-dose

  2. Long-term immune responses to GEN-003 (Serum IgG levels assessed by ELISA)

    Time frame: Up to 48 months post-dose

  3. Long-term immune responses to GEN-003 (Serum HSV-2 neutralizing antibody levels assessed by a colorimetric neutralization assay)

    Time frame: Up to 48 months post-dose

  4. Long-term immune responses to GEN-003 (Spot-forming units (SFUs), fold rise, responder rate assessed by GrB ELISPOT)

    Time frame: Up to 48 months post-dose

07

Study locations

13 sites
  • University of Alabama - Birmingham
    Birmingham, Alabama 35294, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • Quest Clinical Research
    San Francisco, California 94115, United States
  • University of Illinois - Chicago
    Chicago, Illinois 60612, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • The Fenway Institute
    Boston, Massachusetts 02215, United States
  • University of North Carolina
    Chapel Hill, North Carolina 27599, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • NW Dermatology and Research
    Portland, Oregon 97210, United States
  • Magee - Women's Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • Tekton Research
    Austin, Texas 78745, United States
  • Center for Clinical Studies
    Houston, Texas 77004, United States
  • University of Washington
    Seattle, Washington 98104, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02910284
Lead sponsor
Genocea Biosciences, Inc.
Responsible party
Sponsor
First posted
Sep 22, 2016
Start date
Sep 16, 2016
Primary completion
Jul 14, 2017
Completion
Jul 14, 2017
Last update
Oct 20, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion